This trial has been completed.

Conditions copd, disease progression
Treatment telehealth
Sponsor Rocío Prieto Pérez
Collaborator Linde Health Care
Start date December 2013
End date June 2016
Trial size 237 participants
Trial identifier NCT02499068, PROMETE


The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period

The primary endpoint of effectiveness is "severe exacerbations avoided."

The main hypothesis is that patients with severe or very severe COPD patients managed with a home telehealth program have better outcomes than patients managed according to usual clinical practice.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose prevention
Masking no masking
Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
telehealth Telemedicine
Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
(No Intervention)
Patients would do the usual clinical practice.

Primary Outcomes

Number of hospitalizations due to exacerbation of COPD avoided
time frame: 1 year

Secondary Outcomes

Cost-efficiency of treatment
time frame: 1 year
Cost-utility of treatment
time frame: 1 year
satisfaction of both patients and clinician responsibility questionnaire
time frame: 1 year

Eligibility Criteria

All participants from 50 years up to 90 years old.

Inclusion Criteria: - Being over 50 and under 90 years of age. - Being diagnosed with COPD according to the criteria of GesEPOC, with severe airflow obstruction defined as a forced expiratory volume in one second (FEV1) less than 50% of theoretical. - "Exacerbator phenotype" defined as COPD patients having two or more moderate or severe exacerbations per year (GesEPOC guide). These exacerbations should be separated by at least 4 weeks after the end of previous treatment or 6 weeks from the start in cases that have not been treated - Clinically stable condition, defined as 6 weeks without clinical symptoms since the last exacerbation of COPD. - Having home oxygen therapy. - Sign the informed consent. Exclusion Criteria: - Inability of the patient or caregiver to understand the procedure of Telehealth program. - Have a life expectancy of less than one year. - Have terminal heart failure (NYHA functional class III-IV). - Having advanced renal insufficiency (creatinine clearance <30%) or be on dialysis program. - Have liver cirrhosis or be included in a program of liver transplantation. - Be institutionalized or in Residential hospice care. - Having a mini-mental test-score less than 24, because this score suggests dementia - To be considered by your doctor as not comply the treatment or monitoring required by their lung disease. - Failure to meet any of the inclusion criteria.

Additional Information

Official title Proyecto Madrileño Sobre el Manejo de la Enfermedad Pulmonar Obstructiva Crónica Con Telemonitorización a Domicilio. (Multicentre Project on the Home Telemonitoring of Patients With Severe Chronic Obstructive Pulmonary Disease).
Principal investigator Julio Ancochea Bermúdez, MD, PhD
Description Randomized, controlled, multicenter, performance, cost assessment and economic evaluation clinical trial. An arm of the trial will consist of patients assigned to the intervention group (telehealth group: TG ), and the other arm will consist of patients randomized to the control group (routine clinical practice: RCP). For the economic evaluation, the perspective of the health system will be used. Therefore it only direct costs will be considered. In the TG arm also intervention costs it will be considered. Patient selection: Responsible researcher at each hospital center will coordinate the patient selection process. The researchers will identify candidate patients screening through hospital medical records. After this first screening, patients will be contacted and invited to participate in the study. In a personal interview, the researcher explains the study to the patient and deliver the information sheet, verifying that patient meets all inclusion/exclusion criteria, obtains informed consent and then proceeds to patient randomization. To avoid bias from exclusions, researchers will hold record with patient exclusion causes. Every hospital centers will include on average 60 patients (30 in each arm). The inclusion of patients will be competitive; having centers including patients in the study until reaching the final sample size of 120 patients per arm. Randomization: To avoid selection bias, patients assigned to each group will be randomized. To ensure that the number of subjects in each arm is the same, a restrictive block randomization is performed. Randomization is performed using random number generation by computer and the block size of 10 units. Home Telehealth program: Vital sign devices being used: spirometer, pulse oximeter with capacity for heart rate monitor, blood pressure, Visionox® (device capable of measuring respiratory rate, compliance with the hours of oxygen, and the flow and pattern of oxygen used). Devices send data automatically to a modem by Bluetooth. Modem receives and transmits data simultaneously from the monitoring devices to a Central Monitoring Center (CMC). Data received by the modem are encrypted and sent to the telehealth monitoring platform via a 3G signal. The CMC is manned by registered nurses and operates during office hours, 7 days a week. Nurses will attend the patient's home for: the installation of the telehealth devices; to perform a thorough training of the patients / caregivers in the use of equipment and the COPD telehealth program. Patients will perform daily vital sign measurements at the same time, at rest, after administration of the medication and the pattern of oxygen used. Visionox® performs measurements of respiratory rate and oxygen adherence automatically. Measured data will be monitored on a daily bases by the nurses at the CMC. CMC will follow-up information, filter for fle positives and false negatives, and use an application acting as a traffic light system: - Green: meant that measurements had been taken and were within the predefined limits, and no further action was required. - Yellow: "technical alert". This means that the measurements had not been taken or had not been received. This alert could lead to a "clinical alert" due to a lack of adherence or discouragement. When the parameters were not received the nurse at the CMC called the patient to find the reason behind the alert, and either ruled out medical causes or, if one, notified the researcher leading the study. - Red: "clinical alert". Meant that a measurement exceeded the limits that were previously preestablished for each. Classification of severity of clinical alerts is performed by the CMC according to an algorithm. Depending n severity different early medical interventions are taken, or escalated to clinical responsible for early intervention.
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Universidad Autonoma de Madrid.